Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 22, 2026, 5:46 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: ALK Positive Malignancies Clear all
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Relapsed Plasmablastic Lymphoma, Refractory Plasmablastic Lymphoma, Anaplastic Lymphoma Kinase Positive Large B-Cell Lymphoma
Interventions
Belantamab Mafodotin
Drug
Lead sponsor
Jacob Soumerai, MD
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
3
States / cities
Boston, Massachusetts • New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced May 22, 2026, 5:46 AM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Neoplasms, Colorectal Neoplasms, Melanoma, Pancreatic Neoplasms, Sarcoma, Ovarian Neoplasms, Brain Neoplasms, Thyroid Neoplasms, Neuroendocrine Tumors, Cholangiocarcinoma, Salivary Gland Neoplasms, Head and Neck Neoplasms, Thyroid Cancer, Papillary, Lymphoma, Large-Cell, Anaplastic, Neoplasms by Site, Respiratory Tract Neoplasms, Thoracic Neoplasms, Respiratory Tract Diseases, Carcinoma, Bronchogenic, Bronchial Neoplasms, Intestinal Neoplasms, Gastrointestinal Neoplasms, Digestive System Neoplasms, Digestive System Diseases, Gastrointestinal Diseases, Colonic Diseases, Intestinal Diseases, Central Nervous System
Interventions
Alectinib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
29
States / cities
Culver City, California • Los Angeles, California • Sacramento, California + 21 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2023 · Synced May 22, 2026, 5:46 AM EDT
Completed Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
ALK-positive Non Small Cell Lung Cancer (NSCLC) and ROS1-positive NSCLC
Interventions
PF-06463922, Crizotinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
364 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
32
States / cities
Fayetteville, Arkansas • Rogers, Arkansas • Orange, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2024 · Synced May 22, 2026, 5:46 AM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Anaplastic Lymphoma Kinase, Anaplastic Large Cell Lymphoma
Interventions
Alectinib, Duvelisib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced May 22, 2026, 5:46 AM EDT
Completed Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Anaplastic Large Cell Lymphoma, ALK-Negative, Anaplastic Large Cell Lymphoma, ALK-Positive, Hepatosplenic T-Cell Lymphoma, Peripheral T-Cell Lymphoma, Not Otherwise Specified, Stage II Angioimmunoblastic T-cell Lymphoma, Stage II Enteropathy-Associated T-Cell Lymphoma, Stage III Angioimmunoblastic T-cell Lymphoma, Stage III Enteropathy-Associated T-Cell Lymphoma, Stage IV Angioimmunoblastic T-cell Lymphoma, Stage IV Enteropathy-Associated T-Cell Lymphoma
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, Laboratory Biomarker Analysis, Lenalidomide, Peripheral Blood Stem Cell Transplantation, Prednisone, Vincristine Sulfate
Procedure · Drug · Other
Lead sponsor
University of Nebraska
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
8
States / cities
Duarte, California • Palo Alto, California • Aurora, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced May 22, 2026, 5:46 AM EDT
Completed No phase listed Observational Results available
View directory record Official record
Conditions
Non-Small-Cell Lung Carcinoma
Interventions
Alectinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced May 22, 2026, 5:46 AM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Non-small Cell Lung Cancer (NSCLC), Anaplastic Lymphoma Kinase (ALK) Positive
Interventions
gilteritinib
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
8
States / cities
Orange, California • Atlanta, Georgia • Peoria, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced May 22, 2026, 5:46 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Lung Cancer, Nonsmall Cell
Interventions
Crizotinib
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 100 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 10, 2022 · Synced May 22, 2026, 5:46 AM EDT
Terminated Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
ALK-positive Non-small Cell Lung Cancer (NSCLC), RET-positive Non-small Cell Lung Cancer (NSCLC), RET-positive Thyroid Cancer
Interventions
Alectinib
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
4
States / cities
Irvine, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 26, 2021 · Synced May 22, 2026, 5:46 AM EDT
Active, not recruiting Phase 3 Interventional
View directory record Official record
Conditions
Neoplasms
Interventions
Alectinib, Crizotinib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
Not listed
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
2
States / cities
Orange, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced May 22, 2026, 5:46 AM EDT
Active, not recruiting Phase 3 Interventional
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
X-396 (ensartinib), crizotinib
Drug
Lead sponsor
Xcovery Holdings, Inc.
Industry
Eligibility
18 Years and older
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
4
States / cities
Tampa, Florida • Athens, Georgia • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced May 22, 2026, 5:46 AM EDT
Recruiting Not applicable Interventional
View directory record Official record
Conditions
Stage IV Non-small Cell Lung Cancer, Targeted Therapy, Nonsmall Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, ALK-positive Non-small Cell Lung Cancer, EGFR Positive Non-small Cell Lung Cancer, Palliative Care, Survivorship
Interventions
POISE
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 23, 2025 · Synced May 22, 2026, 5:46 AM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
ALK-positive Non-small Cell Lung Cancer
Interventions
Ceritinib, Stereotactic ablative body radiation
Drug · Radiation
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 2, 2023 · Synced May 22, 2026, 5:46 AM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Advanced Malignancies, Positive for Anaplastic Lymphoma Kinase, Positive for Proto-Oncogene Tyrosine-Protein Kinase ROS, Solid Tumor, B-Cell Lymphoma
Interventions
ASP3026
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
6
States / cities
Orange, California • Sacramento, California • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2016 · Synced May 22, 2026, 5:46 AM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Advanced Lung Cancer
Interventions
Ganetespib (STA-9090) and crizotinib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2020 · Synced May 22, 2026, 5:46 AM EDT
No Longer Available No phase listed Expanded access
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Lung Cancer, Advanced Malignancies, Carcinoma
Interventions
Brigatinib
Drug
Lead sponsor
Ariad Pharmaceuticals
Industry
Eligibility
18 Years and older
U.S. locations
3
States / cities
La Jolla, California • Orange, California • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 5, 2018 · Synced May 22, 2026, 5:46 AM EDT
Available No phase listed Expanded access
View directory record Official record
Conditions
Non Small Cell Lung Cancer, ALK-positive Non-small Cell Lung Cancer (NSCLC)
Interventions
NVL-655
Drug
Lead sponsor
Nuvalent Inc.
Industry
Eligibility
18 Years and older
U.S. locations
13
States / cities
Orange, California • Aurora, Colorado • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced May 22, 2026, 5:46 AM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Mature B-Cell Neoplasm, Non Hodgkin Lymphoma, DLBCL, Waldenstrom Macroglobulinemia, MALT Lymphoma, Follicular Lymphoma, Pediatric-Type Follicular Lymphoma, IRF4 Gene Rearrangement, EBV-Positive DLBCL, Nos, Burkitt Lymphoma, Plasmablastic Lymphoma, High-grade B-cell Lymphoma, Primary Cutaneous Follicle Center Lymphoma, Primary Effusion Lymphoma, Mantle Cell Lymphoma, DLBCL Germinal Center B-Cell Type, Primary Mediastinal Large B Cell Lymphoma, T-Cell/Histiocyte Rich Lymphoma, ALK-Positive Large B-Cell Lymphoma, Primary Cutaneous Diffuse Large B-Cell Lymphoma, Splenic Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, Nodal Marginal Zone Lymphoma, HHV8-Positive DLBCL, Nos, Lymphoplasmacytic Lymphoma, Duodenal-Type Follicular Lymphoma
Interventions
SGR-1505
Drug
Lead sponsor
Schrödinger, Inc.
Industry
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
16
States / cities
Gilbert, Arizona • Newark, Delaware • Pompano Beach, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced May 22, 2026, 5:46 AM EDT
Completed Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Carcinoma, NSCLC
Interventions
Ensartinib, Durvalumab
Drug
Lead sponsor
Ludwig Institute for Cancer Research
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 9, 2022 · Synced May 22, 2026, 5:46 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
ALK+ Advanced NSCLC
Interventions
Brigatinib, Alectinib
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
4
States / cities
Whittier, California • Athens, Georgia • Albany, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced May 22, 2026, 5:46 AM EDT
Terminated Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Non-Small Cell Lung Cancer (NSCLC)
Interventions
Alectinib, Bevacizumab
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 12, 2025 · Synced May 22, 2026, 5:46 AM EDT
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
ALK-positive NSCLC, ALK-Positive Lung Cancer, ALK-positive Non-small Cell Lung Cancer
Interventions
TRI-611
Drug
Lead sponsor
TRIANA Biomedicines, Inc.
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2034
U.S. locations
7
States / cities
Aurora, Colorado • St Louis, Missouri • New York, New York + 4 more
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced May 22, 2026, 5:46 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
AUY922
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
4
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 28, 2018 · Synced May 22, 2026, 5:46 AM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Locally Advanced Solid Tumors, Metastatic Solid Tumors
Interventions
Entrectinib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
9
States / cities
Orange, California • San Francisco, California • Aurora, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced May 22, 2026, 5:46 AM EDT